Li YR - Search Results

1

Boosting CAR-T cell therapy through vaccine synergy.

Li YR, Lyu Z, Shen X, Fang Y, Yang L. Li YR, et al. Trends Pharmacol Sci. 2025 Jan 3:S0165-6147(24)00270-0. doi: 10.1016/j.tips.2024.12.004. Online ahead of print. Trends Pharmacol Sci. 2025. PMID: 39755457 Free article. Review.

2

Frontiers in CAR-T cell therapy for autoimmune diseases.

Li YR, Lyu Z, Chen Y, Fang Y, Yang L. Li YR, et al. Trends Pharmacol Sci. 2024 Sep;45(9):839-857. doi: 10.1016/j.tips.2024.07.005. Epub 2024 Aug 14. Trends Pharmacol Sci. 2024. PMID: 39147651 Free article. Review.

3

Managing allorejection in off-the-shelf CAR-engineered cell therapies.

Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Li YR, et al. Mol Ther. 2024 Nov 26:S1525-0016(24)00762-7. doi: 10.1016/j.ymthe.2024.11.035. Online ahead of print. Mol Ther. 2024. PMID: 39600090 Free article. Review.

4

Engineering stem cells for cancer immunotherapy.

Li YR, Zhou Y, Kramer A, Yang L. Li YR, et al. Trends Cancer. 2021 Dec;7(12):1059-1073. doi: 10.1016/j.trecan.2021.08.004. Epub 2021 Sep 1. Trends Cancer. 2021. PMID: 34479851 Review.

5

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.

Li YR, Brown J, Yu Y, Lee D, Zhou K, Dunn ZS, Hon R, Wilson M, Kramer A, Zhu Y, Fang Y, Yang L. Li YR, et al. Cancers (Basel). 2022 Jun 1;14(11):2749. doi: 10.3390/cancers14112749. Cancers (Basel). 2022. PMID: 35681730 Free PMC article.

6

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.

Li YR, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, Fang Y, Yang L. Li YR, et al. Int J Mol Sci. 2022 Jul 7;23(14):7547. doi: 10.3390/ijms23147547. Int J Mol Sci. 2022. PMID: 35886891 Free PMC article.

7

Target tumor microenvironment by innate T cells.

Li YR, Wilson M, Yang L. Li YR, et al. Front Immunol. 2022 Oct 6;13:999549. doi: 10.3389/fimmu.2022.999549. eCollection 2022. Front Immunol. 2022. PMID: 36275727 Free PMC article. Review.

8

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy.

Chen Y, Zhu Y, Kramer A, Fang Y, Wilson M, Li YR, Yang L. Chen Y, et al. Among authors: li yr. Front Med (Lausanne). 2023 Mar 29;10:1135468. doi: 10.3389/fmed.2023.1135468. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37064017 Free PMC article. Review.

9

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.

Li YR, Fang Y, Lyu Z, Zhu Y, Yang L. Li YR, et al. J Transl Med. 2023 Oct 2;21(1):686. doi: 10.1186/s12967-023-04575-9. J Transl Med. 2023. PMID: 37784157 Free PMC article. Review.

10

Advancements in CRISPR screens for the development of cancer immunotherapy strategies.

Li YR, Lyu Z, Tian Y, Fang Y, Zhu Y, Chen Y, Yang L. Li YR, et al. Mol Ther Oncolytics. 2023 Oct 5;31:100733. doi: 10.1016/j.omto.2023.100733. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 37876793 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

883 results

Search Page

Filters